{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:11:26Z","timestamp":1789056686970,"version":"build-2803163510"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"DOI":"10.13039\/501100010909","name":"Excellent Young Scientists Fund","doi-asserted-by":"crossref","award":["82222902"],"award-info":[{"award-number":["82222902"]}],"id":[{"id":"10.13039\/501100010909","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Statin initiation in adults with normal kidney function lowered risks of mortality and major adverse kidney events.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Statins yielded modest yet clinically meaningful absolute risk reductions for mortality and GFR declines.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The observed pleiotropic benefits justified using statins for simultaneous cardiovascular risk reduction and kidney protection.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence on the kidney-protective effects of statins in individuals with normal kidney function is mixed, with some trials suggesting benefits and others raising concerns about AKI. This study evaluates the effect of statin initiation on kidney function in adults with normal kidney function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Sequential target trial emulation on the basis of electronic health records in the Hong Kong Hospital Authority were conducted. Patients aged 18 year or older with normal kidney function (eGFR \u226560 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ) who met the indication for statin therapy (\n                      <jats:italic toggle=\"yes\">i.e<\/jats:italic>\n                      ., LDL-cholesterol \u2265100 mg\/dl without cardiovascular disease or \u226570 mg\/dl with cardiovascular diseases) in Hong Kong between January 2008 and December 2017 were included. Statin initiators and noninitiators were matched using 1:1 propensity score matching. Hazard ratio (HR) and 10-year absolute risk reduction (ARR) of outcomes, including impaired kidney function (eGFR &lt;15 and &lt;60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      ), kidney function deterioration (\u226530% and \u226550% eGFR decline), and all-cause mortality, were estimated using weighted pooled logistic regression on intention-to-treat approach.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 449,595 statin initiators and 449,595 matched noninitiators, statin use was associated with a lower risk of eGFR &lt;15 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (HR, 0.92 [0.90 to 0.95]; ARR, \u22120.33% [\u22120.42% to \u22120.24%]), eGFR &lt;60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (HR, 0.97 [0.96 to 0.98]; ARR, \u22120.98% [\u22121.12% to \u22120.84%]), \u226530% eGFR decline (HR, 0.94 [0.93 to 0.95]; ARR, \u22121.81% [\u22122.00% to \u22121.60%]), \u226550% eGFR decline (HR, 0.90 [0.88 to 0.91]; ARR, \u22120.98% [\u22121.11% to \u22120.85%]), and all-cause mortality (HR [95% confidence interval], 0.90 [0.89 to 0.91]; ARR [95% confidence interval], \u22121.63% [\u22121.76% to \u22121.49%]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Statin initiation in adults with normal kidney function was associated with modestly lower all-cause mortality and kidney function impairment, supporting a potential kidney protective benefit of statins without increasing the risks of adverse kidney outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000001107","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:01:29Z","timestamp":1781647289000},"page":"1511-1520","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A Target Trial Emulation to Investigate Kidney Protection from Statin Initiation in Adults with Normal Kidney Function"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-1575","authenticated-orcid":false,"given":"Franco W.T.","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"School of Pharmacy, The University of Auckland, Auckland, New Zealand"},{"name":"Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy L.","family":"Mak","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0436-3745","authenticated-orcid":false,"given":"Zoey C.T.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7987-7785","authenticated-orcid":false,"given":"Jacqueline J.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-9507","authenticated-orcid":false,"given":"Emily T.Y.","family":"Tse","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-1941","authenticated-orcid":false,"given":"Sydney C.W.","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, School of Clinical Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":false,"given":"Ian C.K.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Aston Centre of Excellence in Pharmacotherapy Optimisation and Pharmacoepidemiology Research, Aston Pharmacy School, Aston University, Birmingham, United Kingdom"},{"name":"School of Pharmacy, Macau University of Science and Technology, Macau Special Administrative Region, China"},{"name":"Advanced Data Analytics for Medical Science Limited, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-1147","authenticated-orcid":false,"given":"Eric Y.F.","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Comprehensive Primary Healthcare Collaboratory, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China"},{"name":"Li Ka Shing Faculty of Medicine, The Institute of Cardiovascular Science and Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"1","key":"B1-20260910","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)."},{"issue":"7","key":"B3-20260910","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1681\/ASN.2015050542","article-title":"CKD prevalence varies across the European general population","volume":"27","author":"Bruck","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B4-20260910","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.kint.2017.12.022","article-title":"Disease burden and challenges of chronic kidney disease in North and East Asia","volume":"94","author":"Wang","year":"2018","journal-title":"Kidney Int."},{"issue":"4S","key":"B5-20260910","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int."},{"key":"B6-20260910","doi-asserted-by":"crossref","first-page":"f880","DOI":"10.1136\/bmj.f880","article-title":"Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases","volume":"346","author":"Dormuth","year":"2013","journal-title":"BMJ."},{"issue":"9","key":"B7-20260910","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1097\/01.ASN.0000143720.71748.79","article-title":"Statin induced proteinuria: renal injury or renoprotection?","volume":"15","author":"Agarwal","year":"2004","journal-title":"J Am Soc Nephrol."},{"issue":"9784","key":"B8-20260910","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"issue":"21","key":"B9-20260910","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med."},{"key":"B11-20260910","doi-asserted-by":"crossref","first-page":"h6926","DOI":"10.1136\/bmj.h6926","article-title":"Cardiovascular outcomes associated with use of clarithromycin: population based study","volume":"352","author":"Wong","year":"2016","journal-title":"BMJ."},{"issue":"5","key":"B12-20260910","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1681\/ASN.0000000554","article-title":"Long-term benefits and safety of statins in patients with kidney failure: a target trial emulation study","volume":"36","author":"Cheng","year":"2025","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B13-20260910","doi-asserted-by":"crossref","first-page":"10317","DOI":"10.1038\/s41467-024-54097-1","article-title":"Myasthenia gravis following statin therapy: evidence from target trial emulation and self-controlled case series study","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun."},{"issue":"3","key":"B14-20260910","doi-asserted-by":"crossref","first-page":"100683","DOI":"10.1016\/j.lanhl.2025.100683","article-title":"Effectiveness and safety of using statin therapy for the primary prevention of cardiovascular diseases in older patients with chronic kidney disease who are hypercholesterolemic: a target trial emulation study","volume":"6","author":"Xu","year":"2025","journal-title":"Lancet Healthy Longev."},{"issue":"6","key":"B15-20260910","doi-asserted-by":"crossref","first-page":"701","DOI":"10.7326\/M24-0004","article-title":"Benefits and risks associated with statin therapy for primary prevention in old and very old adults: real-world evidence from a target trial emulation study","volume":"177","author":"Xu","year":"2024","journal-title":"Ann Intern Med."},{"issue":"5","key":"B16-20260910","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/dom.15503","article-title":"Evaluating different low-density lipoprotein cholesterol thresholds to initiate statin for prevention of cardiovascular diseases in patients with type 2 diabetes mellitus: a target trial emulation study","volume":"26","author":"Wan","year":"2024","journal-title":"Diabetes Obes Metab."},{"key":"B17-20260910","doi-asserted-by":"crossref","first-page":"111425","DOI":"10.1016\/j.jclinepi.2024.111425","article-title":"Long-term statin use and risk of cancers: a target trial emulation study","volume":"172","author":"Xu","year":"2024","journal-title":"J Clin Epidemiol."},{"issue":"25","key":"B18-20260910","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med."},{"issue":"1","key":"B19-20260910","first-page":"39","article-title":"Causal survival analysis: a guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence","volume":"2","author":"Murray","year":"2021","journal-title":"Res Methods Med Health Sci."},{"issue":"3","key":"B20-20260910","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1742-7843.2006.pto_329.x","article-title":"Comparison of dynamic treatment regimes via inverse probability weighting","volume":"98","author":"Hern\u00e1n","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol."},{"issue":"2","key":"B21-20260910","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health."},{"issue":"1","key":"B22-20260910","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J."},{"issue":"12","key":"B23-20260910","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3390\/jcm8122051","article-title":"Statin-induced nitric oxide signaling: mechanisms and therapeutic implications","volume":"8","author":"Gorabi","year":"2019","journal-title":"J Clin Med."},{"issue":"20","key":"B24-20260910","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1111\/bph.17309","article-title":"Off-target effects of statins: molecular mechanisms, side effects and the emerging role of kinases","volume":"181","author":"Lagunas-Rangel","year":"2024","journal-title":"Br J Pharmacol."},{"issue":"5","key":"B25-20260910","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/08860220902835863","article-title":"Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kappaB pathways","volume":"31","author":"Ozbek","year":"2009","journal-title":"Ren Fail."},{"issue":"1","key":"B26-20260910","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/mol.109.061101","article-title":"Pravastatin attenuates carboplatin-induced nephrotoxicity in rodents via peroxisome proliferator-activated receptor alpha-regulated heme oxygenase-1","volume":"78","author":"Chen","year":"2010","journal-title":"Mol Pharmacol."},{"issue":"7","key":"B27-20260910","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1161\/01.CIR.0000138743.09012.93","article-title":"Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins","volume":"110","author":"Haendeler","year":"2004","journal-title":"Circulation."},{"issue":"6","key":"B28-20260910","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","article-title":"Effect of statins on kidney disease outcomes: a systematic review and meta-analysis","volume":"67","author":"Su","year":"2016","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B29-20260910","doi-asserted-by":"crossref","first-page":"16632","DOI":"10.1038\/s41598-019-53064-x","article-title":"Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis","volume":"9","author":"Esmeijer","year":"2019","journal-title":"Sci Rep."},{"issue":"3","key":"B30-20260910","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B31-20260910","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.atherosclerosis.2018.11.015","article-title":"Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004-2015","volume":"280","author":"Blais","year":"2019","journal-title":"Atherosclerosis."},{"issue":"7","key":"B32-20260910","doi-asserted-by":"crossref","first-page":"e0132970","DOI":"10.1371\/journal.pone.0132970","article-title":"Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis","volume":"10","author":"Sanguankeo","year":"2015","journal-title":"PLoS One."},{"issue":"19","key":"B33-20260910","doi-asserted-by":"crossref","first-page":"e027516","DOI":"10.1161\/JAHA.122.027516","article-title":"Association of low-density lipoprotein cholesterol levels during statin treatment with cardiovascular and renal outcomes in patients with moderate chronic kidney disease","volume":"11","author":"Yen","year":"2022","journal-title":"J Am Heart Assoc."},{"issue":"7","key":"B34-20260910","doi-asserted-by":"crossref","first-page":"e024937","DOI":"10.1136\/bmjopen-2018-024937","article-title":"Descriptive analysis of real-world medication use pattern of statins and antiplatelet agents among patients with acute coronary syndrome in Hong Kong and the USA","volume":"9","author":"Wang","year":"2019","journal-title":"BMJ Open."},{"issue":"7","key":"B35-20260910","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1742-1241.2011.02706.x","article-title":"Adherence to lipid-lowering agents among 11,042 patients in clinical practice","volume":"65","author":"Wong","year":"2011","journal-title":"Int J Clin Pract."},{"issue":"7","key":"B36-20260910","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/ndt\/gfm109","article-title":"Delaying initiation of dialysis till symptomatic uraemia--is it too late?","volume":"22","author":"Tang","year":"2007","journal-title":"Nephrol Dial Transplant."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:00:39Z","timestamp":1789056039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001107","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2026-01-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}